Oral hypoglycemic drugs: Pathophysiological basis of their mechanism of action

Pharmaceuticals

Volumn 3, Issue 9, 2010, Pages 3005-3020

  Lorenzati, Bartolomeo ^a   Zucco, Chiara ^a   Miglietta, Sara ^a   Lamberti, Federico ^a   Bruno, Graziella ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Hypoglycemic drugs; Incretin mimetics; Sulfonylureas; Thiazolidinediones

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; INCRETIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; UNINDEXED DRUG; VILDAGLIPTIN;

ABDOMINAL DISCOMFORT; ACUTE HEMORRHAGIC PANCREATITIS; ACUTE PANCREATITIS; ANOREXIA; BACKACHE; BLOATING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DIET THERAPY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVATION; EVENING DOSAGE; EXERCISE; FLATULENCE; FRACTURE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GLUCONEOGENESIS; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LEG PAIN; NAUSEA; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOARTHRITIS; PERIPHERAL EDEMA; RECOMMENDED DRUG DOSE; RETINA MACULA EDEMA; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STROKE; TASTE DISORDER; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 77957314296     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3093005     Document Type: Review

References (62)

1. Bailey, J.; Turner, R.C. Metformin. N. Engl. J. Med. 1996, 334, 574-579.
2. DeFronzo, R.A.; Goodman, A.M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N. Engl. J. Med. 1995, 333, 541-549.
3. Johansen, K. Efficacy of metformin in the treatment of NIDDM: a metanalysis. Diabetes Care 1999, 22, 33-37.
4. Campbell, I.W.; Howlett, H.C.S. Worldwide experience of metformin as an effective glucose lowering agent: a metanalysis. Diabetes Metab. Rev. 1995, 11, 57-62.
5. Currie, C.J.; Poole, C.D.; Gale, E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52, 1766-1777.
6. Tahrani, A.A.; Varughese, G.I.; Scarpello, J.H.; Hanna, F.W. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? Br. Med. J. 2007, 335, 508-512.
7. Owen, M.R.; Doran, E.; Halestrap, A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 2000, 348, 607-614.
8. Bruijstens, L.A.; van Luin, M.; Buscher-Jungerhans, P.M.M; Bosch, F.H. Reality of severe metformin-induced lactic acidosis in the absence of chronic renal impairment. Netherlands J. Med. 2008, 66, 185-190.
9. McCormack, J.; Johns, K.; Tildesley, H. Metformin contraindications should be contraindicated. Ca. Med. Ass. J. 2005, 173, 502-504.
10. Aguilar-Bryan, L.; Nichols, C.G.; Wechsler, S.W.; Clement, J.P.; Boyd, A.E.; González, G.; Herrera-Sosa, H,; Nguy, K.; Bryan, J.; Nelson, D.A. Cloning the ß cell high-affinity sulfonylurea receptor: A regulator of insulin secretion. Science 1995, 268, 423-426.
11. Bressler, R.; Johnson, D.G. Pharmacological regulation of blood glucose levels in non-insulindependent diabetes mellitus. Arch. Intern. Med. 1997, 157, 836-848.
12. Malmberg, K.; The DIGAMI Study Group. Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. Br. Med. J. 1997, 314, 1512-1515.
13. Monami, M.; Balzi, D.; Lamanna, C.; Barchielli, A.; Masotti, G.; Buiatti, E.; Marchionni, N.; Mannucci, E. Are sulphonylureas all the same? A cohort study on cardiovascular and cancerrelated mortality. Diabetes Metab. Res. Rev. 2007, 23, 479-484.
14. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352, 837-853, (Published erratum appears in Lancet 1999, 354, 602).
15. ADVANCE Collaborative Group; Patel, A.; MacMahon, S.; Chalmers, J.; Neal, B., Billot, L.; Woodward, M.; Marre, M.; Cooper, M.; Glasziou, P.; Grobbee, D.; Hamet, P.; Harrap, S.; Heller, S.; Liu, L.; Mancia, G.; Mogensen, C.E.; Pan, C.; Poulter, N.; Rodgers, A.; Williams, B.; Bompoint, S.; de Galan, B.E.; Joshi. R.; Travert, F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Eng.l J. Med. 2008, 358, 2560-2572.
16. DeFronzo, R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. 1999, 131, 281-303.
17. Zoungas, S.; de Galan, B.E.; Ninomiya, T.; Grobbee, D.; Hamet, P.; Heller, S.; MacMahon, S.; Marre, M.; Neal, B.; Patel, A.; Woodward, M.; Chalmers, J, ADVANCE Collaborative Group; Cass, A.; Glasziou, P.; Harrap, S.; Lisheng, L.; Mancia, G.; Pillai, A.; Poulter, N.; Perkovic, V.; Travert, F. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from ADVANCE trial. Diabetes Care 2009, 32, 2068-2074.
18. Tessier, D.; Dawson, K.; Tetrault, J.P.; Bravo, G.; Meneilly, G.S. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet. Med. 1994, 11, 974-980.
19. Fuhlendorff, J.; Rorsman, P.; Kofod, H.; Brand, C.L,; Rolin, B.; MacKay, P.; Shymko, R.; Carr, R.D. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998, 47, 345-351.
20. Black, O.; Donnelly, P.; McIntyre, L.; Royle, P.L.; Shepherd, J.P., Thomas, S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2007, 2, CD004654.
21. Hasslacher, C. Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003, 26, 886-891.
22. Yki-Jarvinen, H. Drug Therapy: Thiazolidinediones. N. Engl. J. Med. 2004, 351, 1106-1118.
23. Petersen, K.F.; Krssak, M.; Inzucchi, S.; Cline, G.W.; Dufour, S.; Shulman, G.I. Mechanism of troglitazone action in type 2 diabetes. Diabetes 2000, 49, 827-831.
24. Kolak, M.; Yki-Jarvinen, H.; Kannisto, K. Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 2007, 92, 720-724.
25. Vidal-Puig, A.J.; Considine, R.V.; Jimenez-Linan, M.; Werman, A.; Pories, W.J.; Caro, J.F.; Flier, J.S. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 1997, 99, 2416-2422.
26. Park, K.S.; Ciaraldi, T.P.; Abrams-Carter, L.; Mudaliar, S.; Nikoulina, S.E.; Henry, R.R. PPARgamma Gene Expression is Elevated In Skeletal Muscle of Obese and Type II Diabetic Subjects. Diabetes 1997, 46, 1230-1234.
27. Sharma, A.M.; Staels, B. Review: Peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism. J. Clin. Endocrinol. Metab. 2007, 92, 386-395.
28. Nissen, S.E.; Wolski, K.; Topol, E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005, 294, 2581-2586.
29. Henry, R.R.; Lincoff, A.M.; Mudaliar, S.; Rabbia, M.; Chognot, C.; Herz, M.; Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009, 374, 126-135.
30. Stocker, D.J.; Taylor, A.J.; Langley, R.W.; Jezior, M.R.; Vigersky, R.A. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am. Heart J. 2007, 153, 445.e1-6.
31. Mazzone, T.; Meyer, P.M.; Feinstein, S.B.; Davidson, M.H.; Kondos, G.T.; D'Agostino, R.B.; Sr, Perez, A.; Provost, J.C.; Haffner, S.M.;Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006, 296, 2572-2581.
32. Uwaifo, G.I.; Ratner, R.E. Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. Am. J. Cardiol. 2007, 99, 51B-67B.
33. Nissen, S.E.; Nicholls, S.J.; Wolski, K.; Nesto, R.; Kupfer, S.; Perez, A.; Jure, H.; De Larochellière, R.; Staniloae, C.S.; Mavromatis, K.; Saw, J., Hu, B.; Lincoff, A.M.; Tuzcu, E.M. PERISCOPE Investigators; Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008, 299, 1561-1573.
34. Nissen, S.E.; Wolski, K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N. Engl. J. Med. 2007, 356, 2457-2471.
35. Lincoff, A.M.; Wolski, K.; Nicholls, S.J.; Nissen, S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298, 1180-1188.
36. Rosen, C.J. The Rosiglitazone Story - Lessons from an FDA Advisory Committee Meeting. N. Engl. J. Med. 2007, 357, 844-846.
37. Singh, S. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 298, 1189-1195.
38. Richter, B.; Bandeira-Echtler, E.; Bergerhoff, K.; Clar, C.; Ebrahim, S.H. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2007, 3. Art. No.: CD006063; doi: 10.1002/14651858.CD006063.pub2.
39. Diamond, G.A.; Bax, L.; Kaul, S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann. Intern. Med. 2007, 147, 578-581.
40. Home, P.D.; Pocock, S.J.; Beck-Nielsen, H.; Gomis, R.; Hanefeld, M.; Dargie, H.; Komajda, M.; Gubb, J.; Biswas, N.; Jones, N.P. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005, 48, 1726-1735.
41. Home, P.D.; Pocock, S.J.; Beck-Nielsen, H.; Curtis, P.S.; Gomis, R.; Hanefeld, M.; Jones, N.P.; Komajda, M.; McMurray, J.J. RECORD Study Team;Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373, 2125-2135.
42. Dormandy, J.A.; Charbonnel, B.; Eckland, D.J.; Erdmann, E.; Massi-Benedetti, M.; Moules, I.K.; Skene, A.M.; Tan, M.H.; Lefèbvre, P.J.; Murray, G.D.; Standl, E.; Wilcox, R.G.; Wilhelmsen, L.; Betteridge, J.; Birkeland, K.; Golay, A.; Heine, R.J.; Korányi, L.; Laakso, M.; Mokán, M.; Norkus, A.; Pirags, V.; Podar, T.; Scheen, A.; Scherbaum, W.; Schernthaner, G.; Schmitz, O.; Skrha, J.; Smith, U.; Taton, J. PROactive investigators; Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005, 366, 1279-1289.
43. Guan, Y.; Hao, C.; Cha, D.R. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat. Med. 2005, 11, 861-866.
44. Kahn, S.E.; Haffner, S.M.; Heise, M.A.; Rao, R.; Lu, W.; Kohan, D.E.; Magnuson, M.A.; Redha, R.; Zhang, Y.; Breyer, M.D. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 2006, 355, 2427-2443.
45. Chiasson, J.L.; Josse, R.G.; Hunt, J.A.; Palmason, C.; Rodger, N.W.; Ross, S.A.; Ryan, E.A.; Tan, M.H.; Wolever, T.M. The efficacy of acarbose in the treatment of patients with non-insulindependent diabetes mellitus. A multicenter controlled clinical trial. Ann. Intern. Med. 1994, 121, 928-935.
46. Chee, W.; Egan, C.; Egan, J.M. Incretin-Based Therapies in Type 2 Diabetes Mellitus. Curr. Protein Pept. Sci. 2009, 10, 46-55.
47. Rocca, A.S.; Brubaker, P.L. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 1999, 140, 1687-1694.
48. Demuth, H.U.; McIntosh, C.H.; Pederson, R.A. Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors. Biochim. Biophys. Acta 2005, 1751, 33-34.
49. Abraham, E.J.; Leech, C.A.; Lin, J.C.; Zulewski, H.; Habener, J.F. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 2002, 143, 3152-3161.
50. Drucker, D.J. The biology of incretin hormones. Cell. Metab. 2006, 3, 153-65.
51. Kolterman, O.G.; Buse, J.B.; Fineman, M.S.; Gaines, E.; Heintz, S.; Bicsak, T.A.; Taylor, K.; Kim, D.; Aisporna, M.; Wang, Y.; Baron, A.D.; Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 2003, 88, 3082-3089.
52. Verspohl, E.J. Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors Pharmacol. Ther. 2009, 124, 113-138.
53. Buse, J.B.; Henry, R.R.; Han, J.; Kim, D.D.; Fineman, M.S.; Baron, A.D. Exenatide-113 Clinical Study Group; Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylureatreated patients with type 2 diabetes. Diabetes Care 2004, 27, 2628-2635.
54. Drucker, D.J.; Buse, J.B.; Taylor, K.; Kendall, D.M.; Trautmann, M.; Zhuang, D.; Porter, L. DURATION-1 Study Group; Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372, 1240-1250.
55. Heine, R.J.; Van Gaal, L.F.; Johns, D.; Mihm, M.J.; Widel, M.H.; Brodows, R.G. GWAA Study Group; Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann. Intern. Med. 2005, 143, 559-569.
56. De Fronzo, R.A.; Ratner, R.E.; Han, J.; Kim, D.D.; Fineman, M.S.; Baron, A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin treated patients with type 2 diabetes. Diabetes Care 2005, 28, 1092-1100.
57. FDC reports. The Pink Sheet. 2008, 70, 9.
58. Juhl, C.B.; Hollingdal, M.; Sturis, J.; Jakobsen, G.; Agersø, H.; Veldhuis, J.; Pørksen, N.; Schmitz, O. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reducesfasting and postprandial glycemia in type 2 diabetes. Diabetes 2002, 51, 424-429.
59. Kim, D.; MacConell, L.; Zhuang, D.; Kothare, P.A.; Trautmann, M.; Fineman, M.; Taylor, K. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007, 30, 1487-1493.
60. Bergman, A.J.; Cote, J.; Yi, B.; Marbury, T.; Swan, S.K.; Smith, W.; Gottesdiener, K.; Wagner, J.; Herman, G.A. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007, 30, 1862-1864.
61. Wright, D.; Maes, A.L.; Yi, B.; Liu, Q.; Johnson-Levonas, A.O.; Wagner, J.A. Multiple dose administration ofMK-0431 (sitagliptin), an inhibitor of dipeptidyl peptidase-IV, does not meaningfully alter the plasma pharmacokinetics or pharmacodynamics of single doses of warfarin. Clin. Pharmacol. Ther. 2006, 79, 76-76.
62. Wani, J.H.; John-Kalarickal, J.; Fonseca, V.A. Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. Cardiol. Clin. 2008, 26, 639-648.